Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Phase of Trial: Phase II/III
Latest Information Update: 14 Apr 2018
At a glance
- Drugs Dupilumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Acronyms LIBERTY ASTHMA TRAVERSE; TRAVERSE
- Sponsors Sanofi
- 08 Feb 2018 Planned End Date changed from 26 Sep 2019 to 1 Nov 2019.
- 08 Feb 2018 Planned primary completion date changed from 26 Sep 2019 to 1 Nov 2019.
- 24 Jan 2018 Planned End Date changed from 2 Oct 2019 to 26 Sep 2019.